Impact of HPV-Related Head and Neck Cancer in Clinical Trials

Opportunity to Translate Scientific Insight into Personalized Care

Christine H. Chung, David Schwartz

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Patients with human papillomavirus (HPV)-positive squamous cell carcinoma of the oropharynx (SCCOP) enjoy better treatment outcomes than patients suffering from HPV-negative head and neck cancer. To maintain the integrity and utility of future clinical trials, HPV-positive SCCOP must be studied as a distinct entity. The discovery of HPV-positive disease has (1) convoluted comparison of current phase II trial data to historical controls, (2) made formal stratification for HPV infection status an imperative for future phase III trial design, and (3) drawn focus toward opportunities for personalization of treatment intensity. This review discusses these research issues.

Original languageEnglish (US)
Pages (from-to)795-806
Number of pages12
JournalOtolaryngologic Clinics of North America
Volume45
Issue number4
DOIs
StatePublished - Aug 1 2012
Externally publishedYes

Fingerprint

Head and Neck Neoplasms
Clinical Trials
Oropharynx
Squamous Cell Carcinoma
Papillomavirus Infections
Research
Therapeutics

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Cite this

Impact of HPV-Related Head and Neck Cancer in Clinical Trials : Opportunity to Translate Scientific Insight into Personalized Care. / Chung, Christine H.; Schwartz, David.

In: Otolaryngologic Clinics of North America, Vol. 45, No. 4, 01.08.2012, p. 795-806.

Research output: Contribution to journalReview article

@article{c2593834753a4028897539b6381732c5,
title = "Impact of HPV-Related Head and Neck Cancer in Clinical Trials: Opportunity to Translate Scientific Insight into Personalized Care",
abstract = "Patients with human papillomavirus (HPV)-positive squamous cell carcinoma of the oropharynx (SCCOP) enjoy better treatment outcomes than patients suffering from HPV-negative head and neck cancer. To maintain the integrity and utility of future clinical trials, HPV-positive SCCOP must be studied as a distinct entity. The discovery of HPV-positive disease has (1) convoluted comparison of current phase II trial data to historical controls, (2) made formal stratification for HPV infection status an imperative for future phase III trial design, and (3) drawn focus toward opportunities for personalization of treatment intensity. This review discusses these research issues.",
author = "Chung, {Christine H.} and David Schwartz",
year = "2012",
month = "8",
day = "1",
doi = "10.1016/j.otc.2012.04.002",
language = "English (US)",
volume = "45",
pages = "795--806",
journal = "Otolaryngologic Clinics of North America",
issn = "0030-6665",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Impact of HPV-Related Head and Neck Cancer in Clinical Trials

T2 - Opportunity to Translate Scientific Insight into Personalized Care

AU - Chung, Christine H.

AU - Schwartz, David

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Patients with human papillomavirus (HPV)-positive squamous cell carcinoma of the oropharynx (SCCOP) enjoy better treatment outcomes than patients suffering from HPV-negative head and neck cancer. To maintain the integrity and utility of future clinical trials, HPV-positive SCCOP must be studied as a distinct entity. The discovery of HPV-positive disease has (1) convoluted comparison of current phase II trial data to historical controls, (2) made formal stratification for HPV infection status an imperative for future phase III trial design, and (3) drawn focus toward opportunities for personalization of treatment intensity. This review discusses these research issues.

AB - Patients with human papillomavirus (HPV)-positive squamous cell carcinoma of the oropharynx (SCCOP) enjoy better treatment outcomes than patients suffering from HPV-negative head and neck cancer. To maintain the integrity and utility of future clinical trials, HPV-positive SCCOP must be studied as a distinct entity. The discovery of HPV-positive disease has (1) convoluted comparison of current phase II trial data to historical controls, (2) made formal stratification for HPV infection status an imperative for future phase III trial design, and (3) drawn focus toward opportunities for personalization of treatment intensity. This review discusses these research issues.

UR - http://www.scopus.com/inward/record.url?scp=84863876312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863876312&partnerID=8YFLogxK

U2 - 10.1016/j.otc.2012.04.002

DO - 10.1016/j.otc.2012.04.002

M3 - Review article

VL - 45

SP - 795

EP - 806

JO - Otolaryngologic Clinics of North America

JF - Otolaryngologic Clinics of North America

SN - 0030-6665

IS - 4

ER -